Get started
NOVARTIS AGNOVARTIS AGNOVARTIS AG

NOVARTIS AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Bonds

1NOVN trade ideas

Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NYSE:NVS is in a personal buy zone. Target #1 = $110.00 Target #2 = $120.00
NYSE:NVSLong
by WorthlessViews
NVS 1H Swing Long Conservative Trend TradeConservative Trend Trade + long impulse + 1/2 correction + T2 level + support level - biggest volume 2Sp- Calculated affordable stop limit 1 to 2 R/R within 1H range take profit Daily Trend "+ long impulse + 1/2 correction + JOC level + support level - above 1/2 of entire 1D wave at the support level of 1M" Monthly Trend "+ long impulse + 1/2 correction + support level + JOC level - unvolumed manipulation" Yearly Trend "+ long impulse - resistance level + less than a month left and it looks to break + long volume distribution" NVS @NYSE Bought NVS Market, Day Filled 8:27 AM 104.89325 Profit Taker Sell NVS Limit 105.87, GTC Submitted 8:27 AM
NYSE:NVS
by MishaSuvorov
Investing in Health: Reasons Why Novartis AG Stock Stands OutIn an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but also setting new standards in innovation and sustainability. A strong monthly demand imbalance at $97.13 per share has recently taken control. Expecting a decent reaction from this price level in the following weeks.
NYSE:NVSLong
by AlfonsoMoreno
Novartis Strikes $1.01 Bln Deal with Arvinas for Prostate DrugsNovartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV-766. This collaboration marks Novartis' ( NYSE:NVS ) continued commitment to advancing cancer therapies, following its recent tender offer to acquire German cancer drugmaker MorphoSys for $2.9 billion. With a focus on fewer therapeutic areas and geographic markets, Novartis aims to bolster its oncology portfolio with innovative treatments. The agreement entails Novartis ( NYSE:NVS ) acquiring global rights to develop and commercialize ARV-766, making an initial payment of $150 million to Arvinas. Additionally, Novartis will acquire another preclinical-stage candidate, AR-V7, targeting prostate cancer, as part of the deal. ARV-766 represents a promising approach to combat prostate cancer by targeting and degrading androgen receptors, critical components in the progression of the disease. Arvinas' protein degradation platform, upon which ARV-766 is based, has garnered validation through this partnership, according to Truist Securities analyst Srikripa Devarakonda. In addition to the upfront payment, Arvinas stands to receive tiered royalties on sales of the drug, as well as potential milestone payments totaling up to $1.01 billion. This signifies a significant endorsement of Arvinas' innovative approach to developing treatments that leverage the body's natural protein disposal system to eliminate disease-causing proteins. Novartis' ( NYSE:NVS ) collaboration with Arvinas underscores the pharmaceutical industry's ongoing pursuit of novel therapeutic modalities to address unmet medical needs. By harnessing cutting-edge technologies and strategic partnerships, companies like Novartis and Arvinas are driving innovation in the fight against cancer, offering hope to patients worldwide.
NYSE:NVS
by DEXWireNews
Longing Novartis (NVS) Longing Novartis (NVS): A Strategic Investment Amidst Geopolitical Tensions This article presents a compelling rationale for considering a long position in Novartis (NVS) stock. The primary driving factor behind this investment strategy is Novartis' close association with Sandoz (SDZ) following the latter's stock debut last week. Sandoz, a subsidiary of Novartis, is a prominent manufacturer of the generic version of Copaxone, a glatiramer acetate injection widely used in the treatment of relapsing forms of multiple sclerosis. This article examines the strategic advantages of this association, highlighting the potential benefits of Novartis' position in the pharmaceutical market in light of increasing tensions in the Middle East. Sandoz's Role in the Copaxone Market: Sandoz's significance in the pharmaceutical industry cannot be overstated, particularly with its role in manufacturing the generic version of Copaxone, known as Glatopa. This medication contains the same active ingredient, offers comparable clinical benefits, and shares a similar administration process with Copaxone. Notably, Copaxone has historically been one of Teva Pharmaceuticals' most profitable products. Geopolitical Tensions and Consumer Behavior: A critical aspect of this investment thesis revolves around the current escalation of tensions in the Middle East, specifically the Israeli-Palestinian conflict. As geopolitical uncertainties continue to mount in the region, consumers and healthcare providers may seek alternative sources for medications, including those used to treat conditions like multiple sclerosis. This shift in consumer behavior is attributed to concerns about supply chain disruptions and the desire to reduce dependence on Israeli-produced drugs amidst the ongoing conflict.
NYSE:NVSLong
by Helios_Capital_Investment
Candidate for swingtrading? Is Novartis a good candidate for swing trading? It has been in an almost horizontal trend for 5 years. But it is also possible that it may break up based on fundamental conditions (1). Good product portfolio and pipeline and many blockbuster. They pay about half of the profits out to the shareholder. I don't have the stock, but will consider try get into, in the bottom of the trend. Lately, price top and bottom coincide with volume top and bottom. On Volume Balance OVB neutral 22 days back. There's a REC where there might be price breaks up or down. Obs formation does not fit so well with volume, but volume profile is OK. RSI 21 about 50. Oscillators and MA stand on buy one day and sell a week to a month. Considers the stock technically neutral in the medium term. Remember you need do your own research and assessment before buying and selling. Sources (1) www.fool.com (2) Trading view
NYSE:NVS
by scorpiris
Novartis AG (NOVN.vx) bearish scenario:The technical figure Triangle can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine (Lamisil), deferasirox (Exjade), and others. The Triangle has broken through the support line on 03/05/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 12 days towards 80.160 CHF. Your stop loss order according to experts should be placed at 87.480 CHF if you decide to enter this position. Novartis said earnings and sales rose in the first quarter of the year, boosted by its key drugs, including heart failure treatment Entresto. Net income was $2.2 billion, up from $1.8 billion in the same quarter the previous year, on sales that grew to $12.53 billion from $12.41 billion. Analysts expected sales of $12.62 billion. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
SIX:NOVNShort
by legacyFXofficial
2
Novartis (NOVN.vx) bullish scenario:The technical figure Double Bottom can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), deferasirox (Exjade), and others. The Double Bottom has broken through the resistance line on 07/04/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 29 days towards 86.88 CHF. Your stop-loss order according to experts should be placed at 72.50 CHF if you decide to enter this position. Novartis CEO Vas Narasimhan is continuing his shake-up of the giant Swiss drugmaker, announcing a corporate restructuring on Monday that the company says will simplify its organizational chart and bring more than $1 billion in annual savings. Novartis AG NVS announced that the FDA has approved its kinase inhibitor, Vijoice (alpelisib), for the treatment of patients aged two years and above with severe manifestations of PIK3CA-Related Overgrowth Spectrum (“PROS”), requiring systemic therapy. Per the company, following the nod, Vijoice became the first FDA-approved therapy to treat PROS, which includes rare conditions where overgrowths and blood vessel anomalies occur. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
SIX:NOVNLong
by legacyFXofficial
Bullish on Novartis. NVSImmediate targets 94, 95. Invalidation 79. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:NVSLong
by Rykin_Capital